The FDA says its mifepristone safety review will continue into 2027, with a study expected to finish by mid-December and a report due no later than March. The agency says it is mining data on injuries and drug side effects to look for safety concerns not yet identified. After reviewing the findings, it will decide whether to impose restrictions or other changes. Possible effects could include limits on telehealth or mail access, or changes to which health professionals may prescribe the drug, but no new restriction has been announced. The FDA is also considering petitions about prescribing and distribution, while court cases continue to address the drug’s oversight and mail delivery.
TLDR: The FDA expects to finish a safety study of mifepristone by mid-December and release its findings by March 2027. Officials have not decided whether to change prescribing rules or how the drug is distributed, as federal courts continue weighing related legal challenges.
The Food and Drug Administration says its review of mifepristone safety will continue into next year. The agency provided an update in a court-ordered legal filing late Wednesday. The review was ordered by Health Secretary Robert F. Kennedy Jr. and is the first substantive account of the reevaluation described in the filing.
The FDA says it is using a statistical data-mining method to look for safety concerns that may not yet be known. Its data comes from an electronic database that collects reports of medical injuries and drug side effects from major health networks and insurers. The agency’s stated rationale is to identify possible safety concerns; the filing does not describe a broader policy rationale.
The FDA expects to finish a safety study by mid-December this year. It expects to report its findings no later than March 2027. After that report, the agency will decide whether to impose new restrictions or make other changes to how the drug is used. No decision on new restrictions has been announced in the filing described in the report.
Mifepristone was approved by the FDA in 2000. The agency has repeatedly reaffirmed its safety and effectiveness and has eased restrictions over time. Those changes included ending a requirement that the drug be dispensed in person. Mifepristone is used with misoprostol in the two-drug regimen that is the most common form of abortion in the United States.
The current review follows pressure from anti-abortion rights groups and allies in Congress to revisit the drug, with the aim of restricting its use. Those groups have focused on rules that allow doctors to prescribe mifepristone online and send it through the mail. The FDA allowed online prescribing and mail delivery in 2021 during the COVID-19 pandemic. The policy was made permanent in 2023 under President Joe Biden.
That access route has affected the reach of state abortion bans because women can receive the drug by mail. A lawsuit brought by Louisiana alleges that mail delivery undermines the state’s abortion ban. The case is one of several state lawsuits concerning mifepristone that are moving through the courts.
A federal judge directed the FDA to provide an update on its review as part of the Louisiana case. Last month, a three-judge panel of the 5th U.S. Circuit Court of Appeals questioned the merits of Louisiana’s case. The panel also questioned whether the state had legal standing to challenge the FDA’s oversight of the drug. The Supreme Court has blocked changes to mifepristone until it sees the case again, so a ruling by the 5th Circuit would not immediately change the current landscape.
The review is drawing criticism from abortion opponents who had hoped for faster action to curtail use. Gavin Oxley of Americans United for Life called the timeline a lack of “true leadership” by administration officials. He also said the administration was not addressing what his group considers harms caused by the pill. Those statements reflect the group’s position, not findings reported by the FDA in its filing.
The review could lead to changes in access, but the outcome remains unknown. In 2025, CBS News medical correspondent Dr. Celine Gounder said withdrawing FDA approval would be difficult and would quickly draw legal challenges. She said changes based on the review could instead make access more difficult, including limits on telehealth or mail availability, or rules reserving prescribing authority to doctors. Physician assistants and nurses are also currently able to prescribe the drug.
The practical effects depend on what the FDA finds and whether it adopts any proposed changes. The agency is considering petitions about how mifepristone is prescribed and distributed. Potential changes could affect online prescribing, mail delivery, and which health professionals may prescribe the drug. The filing gives no new fee, form, or patient deadline, and it does not announce a compliance process or enforcement plan. Any restriction could narrow current choices, but the review has not yet established that such a restriction will occur.
The immediate steps are set out in the agency’s timeline: completion of the study is expected by mid-December, followed by a report no later than March 2027 and a decision on possible changes. The FDA’s court-ordered update and the pending litigation provide points for continued oversight. Those deadlines and proceedings are the next necessary steps in the review.
James Foster serves as the Senior Correspondent for Inequality and the Social Safety Net at Just Right News, where he brings a principled and nuanced perspective to the most pressing economic challenges facing the nation. With a career dedicated to exploring the intersection of policy and personal responsibility, Foster has become a leading voice in documenting how government programs and economic shifts impact the American family. His reporting is characterized by a commitment to the “human element,” moving beyond cold statistics to highlight the stories of resilience, work, and community that define the modern American experience.
Foster’s perspective is deeply rooted in his upbringing in Birmingham, Alabama. Growing up in a city with a rich industrial heritage and a history of economic transformation, he witnessed firsthand the importance of the dignity of work and the strength of local institutions. In Birmingham, he saw how the most effective safety nets were often those woven by neighbors, faith-based organizations, and local civic groups. This background instilled in him a lifelong skepticism of “one-size-fits-all” solutions from distant bureaucracies, favoring instead the localized, community-driven support systems that he frequently champions in his writing.
Now based in Atlanta, Georgia, Foster operates from one of the most dynamic and rapidly evolving metropolitan hubs in the South. His location provides a front-row seat to the stark contrasts of the modern economy. From the gleaming towers of Atlanta’s financial districts to the struggling neighborhoods on the city’s periphery, Foster finds the stories that illustrate the complexities of upward mobility. His reporting from the Sun Belt serves as a microcosm for the national debate on poverty, highlighting how inflation, housing costs, and labor market shifts affect the working class in real-time.
As the lead for the acclaimed feature series “America’s Balancing Act,” Foster explores the delicate tension between providing a necessary hand up and fostering long-term independence. The series has become a cornerstone of Just Right News, offering a deep dive into the unintended consequences of social welfare policies. Foster’s work often focuses on the “cliff effect” and other systemic hurdles that can inadvertently discourage employment, arguing that true compassion is measured by how many people are empowered to leave the safety net, rather than how many are added to it.
Throughout his tenure, Foster has remained dedicated to the mission of Just Right News, providing a clear-eyed, conservative analysis of social issues. He believes that a free society thrives when individuals are empowered and the private sector is allowed to innovate. Whether he is interviewing small business owners about the challenges of a changing workforce or documenting the success of private charitable initiatives, Foster’s goal is to provide readers with the truth about the state of the American Dream. His work serves as a vital reminder that while the challenges of inequality are great, the solutions are often found in the strength of the American spirit and the preservation of traditional values.